ClinicalTrials.gov Identifier: NCT01492361 First received: December 13, 2011 Last updated: July 25, 2016 Last verified: July 2016
On Friday, 4 days after the update, you can rule out futility. Amarin would have announced a futility as a material event if they stopped enrolling. Instead, Amarin stopped enrolling and the the trial continues while the DSMC continues to evaluate the interim data.
Quote: "Does the fact that many other biotech stocks (with similar price patterns) saw the same type of short squeeze price action on the last day of the month mean that bets were also being placed that their trials will be halted? LOL.."
"LOL" is appropriate..What are you talking about? The NBI (NASDAQ biotech index) was up 1% on Friday...Amarin was up over 10%..Why don't you try telling the truth occasionally.